ICPT Key Stats
- IC Potash Receives Jurisdictional Determination From U.S. Army Corps of Engineer... Jun 11
- Intercept Pharma (ICPT) Files 2M Common Shelf Street Insider Jun 10
- INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other Events May 31
- Nasdaq stocks posting largest percentage increases May 30
- IC Potash Adopts Advance Notice to By-Laws Marketwired May 29
- IC POTASH CORPORATION Financials May 23
- Intercept Pharmaceuticals to Present at Deutsche Bank Healthcare Conference PR Newswire May 23
- Are These Top Post-IPO Performers Still a Buy? Fool May 22
- IC Potash Issues Progress Update on Ochoa Sulphate of Potash Project in New Mexi... May 22
- Intercept Pharmaceuticals Announces Positive Initial Results from Ongoing Phase ... May 20
ICPT Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Intercept Pharmaceuticals is up 0.73% over the last year vs S&P 500 Total Return up 25.82%, KYTHERA Biopharmaceuticals down 2.44%, and Cyanotech Corporation down 22.22%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for ICPT
Pro Report PDF for ICPT
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ICPT Pro Report PDF
Pro Strategies Featuring ICPT
Did Intercept Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.